Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $70.8333.

A number of research analysts have recently commented on CORT shares. Piper Sandler lifted their price objective on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. UBS Group raised shares of Corcept Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $44.00 to $72.00 in a research report on Wednesday, May 13th. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Wolfe Research raised shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a report on Thursday, March 26th.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks lifted several earnings estimates for Corcept Therapeutics, including FY2026 to $0.38 per share from $0.20 and FY2028 to $3.14 from $3.02, suggesting improved long-term profit expectations. Corcept Therapeutics stock page
• Positive Sentiment: Analysts also raised estimates for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027 and Q1 2028, reflecting a more favorable outlook for earnings momentum over the next few years. Corcept Therapeutics stock page
• Neutral Sentiment: Despite the higher targets in several periods, Zacks Research maintained a Hold rating, indicating the outlook is improving but not yet compelling enough for a bullish upgrade. Corcept Therapeutics stock page
• Negative Sentiment: Some longer-term estimates were cut, including Q3 2027 to $0.57 from $0.91 and Q4 2027 to $0.59 from $0.77, which may temper enthusiasm about the pace of future growth. Corcept Therapeutics stock page

Corcept Therapeutics Price Performance

Shares of CORT opened at $60.22 on Friday. The firm has a 50-day moving average of $44.79 and a 200-day moving average of $52.61. Corcept Therapeutics has a one year low of $28.66 and a one year high of $91.00. The company has a market cap of $6.46 billion, a PE ratio of 172.06 and a beta of 0.36.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The firm had revenue of $164.90 million during the quarter, compared to the consensus estimate of $185.83 million. During the same period last year, the business earned $0.17 EPS. The business’s revenue was up 4.9% on a year-over-year basis. Analysts expect that Corcept Therapeutics will post 0.48 earnings per share for the current year.

Insider Buying and Selling

In related news, Director G Leonard Baker, Jr. bought 100,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, March 17th. The stock was acquired at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the acquisition, the director owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. This represents a 9.55% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the sale, the chief executive officer directly owned 2,918,326 shares of the company’s stock, valued at $146,120,582.82. The trade was a 0.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 86,198 shares of company stock valued at $3,887,769. Company insiders own 20.70% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its holdings in shares of Corcept Therapeutics by 33.6% during the 1st quarter. Bank of America Corp DE now owns 111,736 shares of the biotechnology company’s stock worth $4,504,000 after buying an additional 28,078 shares during the period. Edgestream Partners L.P. bought a new stake in shares of Corcept Therapeutics during the 1st quarter worth about $2,790,000. Janus Henderson Group PLC boosted its holdings in shares of Corcept Therapeutics by 7.1% during the 1st quarter. Janus Henderson Group PLC now owns 164,074 shares of the biotechnology company’s stock worth $6,614,000 after buying an additional 10,817 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Corcept Therapeutics during the 1st quarter worth about $322,000. Finally, Amundi bought a new stake in shares of Corcept Therapeutics during the 1st quarter worth about $459,000. Institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.